There was an attempt to buy Amarin in April,2011 after Marine 3 trial results were public.Sun Times reported it and Amarin conformed it in June,2011 to Bloomberg reporter. on 6/10/2011.
It was simply PRICE. Joe wanted 30$ -bidders were offering close to 15$/share.
During last 15 months--Amarin has gotten great results for Anchor 3 trials for 200-500mg.population.
Their patent position has improved--protection thru 2030 looks solid.(Yes,Generics will create trouble if NCE for 5 years is NOT granted)-but patents will have to be enforced by Amarin.
NOW--8 analysts from MKM(21.50) to Jeffries (28$) are all rating it Strong Buy or BUY.
As happened with Warner Lambert in 1997--when Merck and Pfizer were reluctant to pay big money(as results with patients were great--but CONSUMERS WILLING to switch from ZOCOR to LIPITOR was unknown).When Pfizer achieved 18% market share for Lipitor--every one was SHOCKED.
Warner Lambert Value tripled in 1999--when bidding took place.
SAME COULD HAPPEN in 2012--RIGHT PRICE could keep Amarin and PFIZER apart,but ultimately--Merck or Pfizer will buy AMARIN in 2013 .
Do you think that was a lessoned learned and they'll pony up $28-31 soon? I still cannot shake the thought that reduce-it/combo potential is a smart gamble for BP down the road and they would want to lock up amrn now. My magic 8-ball is refusing to answer me anymore when I ask about amrn!